Giant-Cell Arteritis Market to witness growth by 2034, estimates DelveInsight | RINVOQ (upadacitinib), COSENTYX (secukinumab), Mavrilimumab, TREMFYA (guselkumab), more

May 09 07:26 2024
Giant-Cell Arteritis Market to witness growth by 2034, estimates DelveInsight | RINVOQ (upadacitinib), COSENTYX (secukinumab), Mavrilimumab, TREMFYA (guselkumab), more
Giant-Cell Arteritis Market
Giant-Cell Arteritis companies are AbbVie, CSL, Kiniksa Pharmaceuticals, Dr Reddys Laboratories, Eli Lilly and Company, Janssen Biotech, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., MorphoSys AG, Novartis Pharmaceuticals, Roche Holding, XOMA, and several others.

(Albany, USA) DelveInsight’s “Giant-Cell Arteritis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Giant-Cell Arteritis, historical and forecasted epidemiology as well as the Giant-Cell Arteritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Giant-Cell Arteritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Giant-Cell Arteritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Giant-Cell Arteritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Giant-Cell Arteritis market.


Request for a Free Sample Report @ Giant-Cell Arteritis Market Forecast


Some facts of the Giant-Cell Arteritis Market Report are:

  • According to DelveInsight, Giant-Cell Arteritis market size is expected to grow at a decent CAGR by 2034.
  • In 2023, the total Giant-Cell Arteritis market size was around USD 960 million, which is expected to increase by 2034 during the study period (2020–2034) in the 7MM.
  • Leading Giant-Cell Arteritis companies working in the market are AbbVie, CSL, Kiniksa Pharmaceuticals, Dr Reddys Laboratories, Eli Lilly and Company, Janssen Biotech, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., MorphoSys AG, Novartis Pharmaceuticals, Roche Holding, XOMA, and several others.
  • Key Giant-Cell Arteritis Therapies expected to launch in the market are RINVOQ (upadacitinib), COSENTYX (secukinumab), Mavrilimumab, TREMFYA (guselkumab), and many others.
  • On May 2024, Novartis announced results of a Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg and 150 mg Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) (GCAptAIN).
  • On February 2024, AbbVie announced results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis: SELECT-GCA.
  • On April 2024, Janssen Research & Development announced results of a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis.


Giant-Cell Arteritis Overview

Giant cell arteritis (GCA) is a type of vasculitis characterized by inflammation of medium and large arteries, predominantly affecting individuals over 50, particularly women. It often involves the temporal arteries, leading to symptoms such as headaches, jaw pain, and vision disturbances, including blindness if left untreated. Systemic symptoms like fatigue, weight loss, and fever may also occur.

Giant cell arteritis Diagnosis relies on clinical evaluation, supported by laboratory tests showing elevated markers of inflammation and imaging studies revealing arterial wall thickening or stenosis. Prompt treatment with corticosteroids is crucial to prevent complications, such as permanent vision loss or vascular complications like aortic aneurysms. However, long-term corticosteroid use can lead to adverse effects like osteoporosis and infections.

Emerging Giant cell arteritis therapies like tocilizumab offer alternatives for patients intolerant to or dependent on corticosteroids. Despite advances, managing Giant cell arteritis requires close monitoring to balance treatment efficacy with minimizing adverse effects. Collaborative efforts between rheumatologists, ophthalmologists, and other specialists are essential for optimizing patient outcomes and improving quality of life in this chronic inflammatory condition.


Do you know what will be the Giant-Cell Arteritis market share in 7MM by 2034 @


Giant-Cell Arteritis Market 

The Giant-Cell Arteritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Giant-Cell Arteritis market trends by analyzing the impact of current Giant-Cell Arteritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Giant-Cell Arteritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Giant-Cell Arteritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Giant-Cell Arteritis market in 7MM is expected to witness a major change in the study period 2020-2034.


Giant-Cell Arteritis Epidemiology 

The Giant-Cell Arteritis epidemiology section provides insights into the historical and current Giant-Cell Arteritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Giant-Cell Arteritis market report also provides the diagnosed patient pool, trends, and assumptions. 


Interested to know how the emerging diagnostic approaches will be contributing in increased Giant-Cell Arteritis diagnosed prevalence pool? Download report @


Giant-Cell Arteritis Drugs Uptake

This section focuses on the uptake rate of the potential Giant-Cell Arteritis drugs recently launched in the Giant-Cell Arteritis market or expected to be launched in 2020-2034. The analysis covers the Giant-Cell Arteritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Giant-Cell Arteritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Giant-Cell Arteritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Giant-Cell Arteritis Pipeline Development Activities

The Giant-Cell Arteritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Giant-Cell Arteritis key players involved in developing targeted therapeutics.


Download report to know which TOP 3 therapies will be capturing the largest Giant-Cell Arteritis market share by 2034? Click here @


Giant-Cell Arteritis Therapeutics Assessment

Major key companies are working proactively in the Giant-Cell Arteritis Therapeutics market to develop novel therapies which will drive the Giant-Cell Arteritis treatment markets in the upcoming years are AbbVie, CSL, Kiniksa Pharmaceuticals, Dr Reddys Laboratories, Eli Lilly and Company, Janssen Biotech, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., MorphoSys AG, Novartis Pharmaceuticals, Roche Holding, XOMA, and several others.


Do you know how RINVOQ and COSENTYX market launch will be impacting the Giant-Cell Arteritis market CAGR? Download sample report @


Giant-Cell Arteritis Report Key Insights

1. Giant-Cell Arteritis Patient Population

2. Giant-Cell Arteritis Market Size and Trends

3. Key Cross Competition in the Giant-Cell Arteritis Market

4. Giant-Cell Arteritis Market Dynamics (Key Drivers and Barriers)

5. Giant-Cell Arteritis Market Opportunities

6. Giant-Cell Arteritis Therapeutic Approaches

7. Giant-Cell Arteritis Pipeline Analysis

8. Giant-Cell Arteritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Giant-Cell Arteritis Market


Table of Contents

1. Key Insights

2. Executive Summary

3. Giant-Cell Arteritis Competitive Intelligence Analysis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Giant-Cell Arteritis Disease Background and Overview

6. Giant-Cell Arteritis Patient Journey

7. Giant-Cell Arteritis Epidemiology and Patient Population

8. Giant-Cell Arteritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Giant-Cell Arteritis Unmet Needs

10. Key Endpoints of Giant-Cell Arteritis Treatment

11. Giant-Cell Arteritis Marketed Products

12. Giant-Cell Arteritis Emerging Therapies

13. Giant-Cell Arteritis Seven Major Market Analysis

14. Attribute Analysis

15. Giant-Cell Arteritis Market Outlook (7 major markets)

16. Giant-Cell Arteritis Access and Reimbursement Overview

17. KOL Views on the Giant-Cell Arteritis Market

18. Giant-Cell Arteritis Market Drivers

19. Giant-Cell Arteritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States